JP2014500307A5 - - Google Patents

Download PDF

Info

Publication number
JP2014500307A5
JP2014500307A5 JP2013545584A JP2013545584A JP2014500307A5 JP 2014500307 A5 JP2014500307 A5 JP 2014500307A5 JP 2013545584 A JP2013545584 A JP 2013545584A JP 2013545584 A JP2013545584 A JP 2013545584A JP 2014500307 A5 JP2014500307 A5 JP 2014500307A5
Authority
JP
Japan
Prior art keywords
alkyl
aryl
group
independently
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013545584A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014500307A (ja
JP5992435B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2011/055730 external-priority patent/WO2012085789A1/en
Publication of JP2014500307A publication Critical patent/JP2014500307A/ja
Publication of JP2014500307A5 publication Critical patent/JP2014500307A5/ja
Application granted granted Critical
Publication of JP5992435B2 publication Critical patent/JP5992435B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2013545584A 2010-12-21 2011-12-16 循環からの生体分子の除去剤 Active JP5992435B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10196092.0 2010-12-21
EP10196092 2010-12-21
PCT/IB2011/055730 WO2012085789A1 (en) 2010-12-21 2011-12-16 Agents for clearing biomolecules from circulation

Publications (3)

Publication Number Publication Date
JP2014500307A JP2014500307A (ja) 2014-01-09
JP2014500307A5 true JP2014500307A5 (enExample) 2015-10-29
JP5992435B2 JP5992435B2 (ja) 2016-09-14

Family

ID=43530614

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013545584A Active JP5992435B2 (ja) 2010-12-21 2011-12-16 循環からの生体分子の除去剤

Country Status (6)

Country Link
US (1) US9427482B2 (enExample)
EP (1) EP2654796A1 (enExample)
JP (1) JP5992435B2 (enExample)
CN (1) CN103328008B (enExample)
RU (1) RU2013133813A (enExample)
WO (1) WO2012085789A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2709666B1 (en) 2011-05-16 2021-07-14 Koninklijke Philips N.V. Bio-orthogonal drug activation
WO2014081301A1 (en) * 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Bio-orthogonal drug activation
WO2014081300A1 (en) * 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Channel protein activatable liposomes
EP2922574B1 (en) 2012-11-22 2023-05-17 Tagworks Pharmaceuticals B.V. Chemically cleavable group
WO2014081299A1 (en) * 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Activatable liposomes
WO2014205126A1 (en) 2013-06-19 2014-12-24 The Regents Of The University Of California Chemical structures for localized delivery of therapeutic agents
CN106659796B (zh) 2014-03-14 2021-04-30 加利福尼亚大学董事会 Tco缀合物和治疗剂递送方法
WO2016025480A1 (en) 2014-08-11 2016-02-18 The General Hospital Corporation Cyclooctenes for bioorthogonol reactions
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
LT3319959T (lt) 2015-07-06 2021-12-27 Alkermes, Inc. Histono deacetilazės hetero-halogeno inhibitoriai
JP6823067B2 (ja) 2015-09-10 2021-01-27 タンボ・インコーポレイテッド 生体直交型組成物
WO2018004338A1 (en) 2016-06-27 2018-01-04 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
US10222346B2 (en) * 2017-01-09 2019-03-05 National Research Council Of Canada Decomposable S-tetrazine based polymers for single walled carbon nanotube applications
ES2909086T3 (es) 2017-01-11 2022-05-05 Alkermes Inc Inhibidores bicíclicos de histona desacetilasa
ES2983582T3 (es) 2017-04-07 2024-10-23 Tambo Inc Composiciones bioortogonales
ES3057687T3 (en) * 2017-07-06 2026-03-04 Memorial Sloan Kettering Cancer Center Dota-hapten compositions for anti-dota/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy
US11559494B2 (en) 2017-07-14 2023-01-24 The Penn State Research Foundation Compositions and methods for targeted delivery of therapeutic and/or diagnostic species
SG11202000970WA (en) 2017-08-07 2020-02-27 Rodin Therapeutics Inc Bicyclic inhibitors of histone deacetylase
JP2021517564A (ja) 2018-03-12 2021-07-26 メモリアル スローン ケタリング キャンサー センター 二重特異性結合因子およびその使用
WO2020061103A1 (en) 2018-09-18 2020-03-26 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
WO2020247151A1 (en) * 2019-06-05 2020-12-10 Boston Scientific Scimed, Inc. Click chemistry capturable platinum-based antineoplastic agents
CN115135628A (zh) 2019-06-17 2022-09-30 泰克沃尔科斯制药有限公司 快速高效点击释放的化合物
CN114599645A (zh) 2019-06-17 2022-06-07 泰克沃尔科斯制药有限公司 用于在体内从生物分子中裂解标记的试剂
US12589162B2 (en) 2020-08-07 2026-03-31 Tambo, Inc. Trans-cyclooctene prodrug of monomethyl auristatin E
AU2024220523B2 (en) * 2023-02-15 2025-12-11 Tagworks Pharmaceuticals B.V. Tetrazines with improved properties
WO2025166142A1 (en) * 2024-01-31 2025-08-07 Oregon State University Protein labeling in living cells via control of redox state of encoded tetrazines

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075010A (en) 1992-06-09 2000-06-13 Neorx Corporation Small molecular weight ligand-hexose containing clearing agents
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US5326856A (en) 1992-04-09 1994-07-05 Cytogen Corporation Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
US5624896A (en) 1992-06-09 1997-04-29 Neorx Corporation Clearing agents useful in pretargeting methods
US5616690A (en) 1992-06-09 1997-04-01 Neorx Corporation Hexose derivatized human serum albumin clearing agents
US20030129191A1 (en) 1992-12-23 2003-07-10 Neorx Corporation Pretargeting methods and compounds
ATE254631T1 (de) 1993-12-07 2003-12-15 Neorx Corp Pretargeting verfahren und mitteln
WO1995015978A1 (en) 1993-12-07 1995-06-15 Neorx Corporation Pretargeting methods and compounds
US5886143A (en) 1994-12-07 1999-03-23 Neorx Corporation Hepatic-directed compounds and reagents for preparation thereof
US6908903B1 (en) 1994-12-07 2005-06-21 Aletheon Pharmaceuticals, Inc. Cluster clearing agents
US6172045B1 (en) 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
WO1996040245A1 (en) 1995-06-07 1996-12-19 Immunomedics, Inc. Improved delivery of diagnostic and therapeutic agents to a target site
US7052872B1 (en) 1999-06-22 2006-05-30 Immunomedics, Inc. Bi-specific antibodies for pre-targeting diagnosis and therapy
EP1809339A2 (en) 2004-10-07 2007-07-25 Koninklijke Philips Electronics N.V. Compounds, kits and methods for use in medical imaging
EP2026840A2 (en) 2005-10-04 2009-02-25 Koninklijke Philips Electronics N.V. Targeted imaging and/or therapy using the [3+2]-azide-alkyne cycloaddition
WO2010051530A2 (en) 2008-10-31 2010-05-06 The General Hospital Corporation Compositions and methods for delivering a substance to a biological target
BRPI1006246A2 (pt) * 2009-04-16 2020-02-04 Koninl Philips Electronics Nv "kit para imagem médica marcada e/ou terapias, sonda efetora e método"
US20120039803A1 (en) * 2009-04-16 2012-02-16 Koninklijke Philips Electronics N.V. Pretargeting kit, method and agents used therein
AU2011343995A1 (en) 2010-12-13 2013-06-20 Biomimetic Therapeutics, Llc Compositions and methods for spine fusion procedures

Similar Documents

Publication Publication Date Title
JP5992435B2 (ja) 循環からの生体分子の除去剤
JP6368745B2 (ja) プレターゲットキット、プレターゲット方法及びその使用試薬
EP2419142B1 (en) Pretargeting kit, method and agents used therein
US9913921B2 (en) Pretargeting kit for imaging or therapy comprising a trans-cyclooctene dienophile and a diene
JP2014506869A5 (enExample)
CN102438656B (zh) 预靶向试剂盒、方法和其中使用的试剂
EP4424713A2 (en) Agents for cleaving labels from biomolecules in vivo
CN103269721B (zh) 预靶向试剂盒、方法和其中使用的试剂